Table 1

Initial characteristics of the 30 patients included in the trial

Overall population N=30Control group N=15intravenous IG group N=15
Age, years, median (Q1–Q3)10.6 (4–14.1)13.1 (4–14.1)7.1 (3.1–13.0)
Weight, kg, median (Q1–Q3)35.0 (17–50)48.0 (7.8–56)35.0 (15–40)
Sex, female, N (%)15 (50)9 (60)6 (40)
PELOD-2 Score, median (Q1–Q3)6 (4–8)6 (4–7)6 (5–9)
PIM-3, median (Q1–Q3)3.5 (1.9–939)3.2 (1.5–39.0)4.8 (2.2–51.3)
Age-adjusted hypotension, N (%)18 (60)8 (53.3)10 (66.7)
Fever>38.5°C, N* (%)7 (41)2 (33)5 (45.5)
Vomiting, N (%)17 (57)7 (47)10 (67)
Diarrhoea, N (%)17 (57)8 (53)9 (60)
Neurological injury, N (%)9 (30)3 (20)6 (40)
Muscular injury, N (%)13 (43)5 (33)8 (53)
Cutaneous signs
 Desquamation, N (%)1 (3)1 (7)0 (0)
 Rash, N (%)25 (83)13 (87)12 (80)
 Skin necrosis, N (%)2 (7)1 (7)1 (7)
 Mucosal lesion, N (%)13 (43)6 (40)7 (47)
Minimum leucocyte count (G/L), median (Q1–Q3)10.8 (8.1–14.1)11.11 (8.11–16.1)10.6 (6.6–12.7)
Minimum lymphocyte count (G/L), median (Q1–Q3) (N=17)0.4 (0.2–0.7)0.44 (0.2–1.3)0.44 (0.3–0.7)
Minimum platelet value (G/L), median (Q1–Q3)109.5 (84–143)96 (74–155)115 (94–143)
Disseminated intravascular coagulation, N (%)11 (37)7 (47)4 (27)
Liver alterations†, N (%)24 (80)11 (73)13 (87)
Maximum creatinine value (µmol/L), median (Q1–Q3)99 (53–150)115 (39–147)79 (53–184)
Maximum PCT value (µg/mL), median (Q1–Q3) (N=25)75 (54–122)71 (60–100)88 (50–300)
Maximum lactate value (mmol/L), median (Q1–Q3)2.8 (2.3–40)2.8 (2.3–3.6)3.4 (2.4–4.3)
Maximum CK value (UI/L), median (Q1–Q3) (N=21)353 (129–1283)336 (67–775)387 (295–1283)
  • *N=26.

  • †Liver alterations were defined as: aspartate aminotransferase>3N or alanine aminotransferase>3N according to normal values for age or prothormbin ratio (PR)<70%

  • CK, creatine kinase; IG, immunoglobulin; PCT, procalcitonin; PELOD-2, Pediatric Logistic Organ Dysfunction-2; PIM 3, Pediatric Index of Mortality-3.